PRAXBIND
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PRAXBIND (PRAXBIND).
Idarucizumab is a humanized monoclonal antibody fragment (Fab) that binds specifically to dabigatran and its acylglucuronide metabolites with high affinity (approximately 350-fold higher than the affinity of dabigatran for thrombin), neutralizing their anticoagulant effect in a concentration-dependent manner.
| Metabolism | Idarucizumab is a monoclonal antibody fragment, not metabolized by cytochrome P450 enzymes; it is degraded via catabolic pathways to small peptides and amino acids. |
| Excretion | Primarily renal: ~80% of the dose is excreted unchanged in urine within 6-12 hours. A small fraction (approximately 1-2%) undergoes hepatic metabolism via amidase cleavage to form a carboxylic acid metabolite (M2), which is excreted renally. Fecal excretion accounts for <5%. |
| Half-life | Terminal elimination half-life is approximately 1.1 hours (range 0.9-1.4 hours) in healthy subjects. This short half-life allows rapid reversal of anticoagulant effect; however, sustained reversal requires continuous intravenous infusion due to idarucizumab's own elimination. |
| Protein binding | Idarucizumab exhibits negligible protein binding (<1%) as it is a humanized monoclonal antibody fragment. |
| Volume of Distribution | Volume of distribution is approximately 0.8 L/kg (range 0.4-1.2 L/kg), indicating distribution primarily within the extracellular fluid space, consistent with a large protein molecule. |
| Bioavailability | Not applicable for intravenous administration; bioavailability is 100% when given IV. |
| Onset of Action | Intravenous bolus: Reversal of anticoagulant effect begins within minutes; 100% reversal of dabigatran anticoagulant activity is achieved within 5 minutes as measured by diluted thrombin time or ecarin clotting time. |
| Duration of Action | After a single 5 g IV dose, reversal of dabigatran-induced anticoagulation is sustained for up to 24 hours based on clotting assays. However, clinical duration may be shorter if dabigatran has a prolonged half-life (e.g., renal impairment), and reversal may diminish as idarucizumab is cleared. Re-dosing may be required if dabigatran levels rebound. |
| Molecular Weight | 47600 |
5 g intravenous bolus, followed by a second 5 g dose if needed (max 10 g total). Administer as two consecutive 50 mL infusions over 5-10 minutes each.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required for renal impairment. Idarucizumab is not removed by dialysis. |
| Liver impairment | No dose adjustment required for hepatic impairment. |
| Pediatric use | Safety and efficacy not established in pediatric patients. No approved dosing guidelines. |
| Geriatric use | No specific dose adjustment required. Use standard dosing based on clinical response and bleeding severity. |
| 1st trimester | No adequate human data; animal studies not conducted. Use only if benefit outweighs risk. |
| 2nd trimester | No adequate human data; animal studies not conducted. Use only if benefit outweighs risk. |
| 3rd trimester | Use only if clearly needed; potential risk of bleeding in mother or fetus. |
Clinical note
Comprehensive clinical and safety monograph for PRAXBIND (PRAXBIND).
| Placental transfer | Highly active, large monoclonal antibody (idarucizumab is a fragment) expected to cross placenta minimally; no data. |
| Breastfeeding | Not known if excreted in human milk; caution due to potential for adverse reactions in infant. |
| Lactation Rating |
■ FDA Black Box Warning
None.
| Common Effects | Diarrhea Stomach pain |
| Serious Effects |
Hypersensitivity to idarucizumab or any component
| Precautions | Thromboembolic risk: Reversal of anticoagulant effects may expose patients to the thrombotic risk of their underlying disease. Reinitiate anticoagulation as soon as medically appropriate., Hypersensitivity reactions: Allergic reactions (including anaphylaxis) have been reported., Re-elevation of dabigatran levels: In patients with severe renal impairment (CrCl ≤30 mL/min) or those who received a second dose of dabigatran within 12 hours after idarucizumab, dabigatran levels may re-elevate. Monitor for rebleeding and consider repeat dosing., Not for use in patients not on dabigatran therapy. |
| Food/Dietary | No known food interactions. Administer regardless of meals. |
Loading safety data…
| L3 (Moderately Safe) |
| Teratogenic Risk | PRAXBIND (idarucizumab) is a monoclonal antibody fragment. No adequate human studies; animal studies not reproductive. Theoretical risk of fetal harm is low due to IgG class crossing placenta only after first trimester, but no direct teratogenic effects known. Use only if clearly needed. |
| Fetal Monitoring | Monitor coagulation parameters (aPTT, dTT, ECT) and clinical signs of bleeding. Fetal monitoring: standard obstetric surveillance; no specific fetal drug monitoring required. |
| Fertility Effects | No human data on fertility effects. Animal studies not conducted. Not expected to impact fertility based on mechanism of action. |
| Clinical Pearls | Monitor aPTT and ECT (ecarin clotting time) to assess reversal effect. Administer via IV bolus over 5–10 minutes; for life-threatening bleeding, consider a second 5 g dose if ongoing bleeding. Rebound anticoagulation may occur due to idarucizumab's short half-life (~1 hour) vs dabigatran's (~12–17 hours). Hepatic impairment does not require dose adjustment, as metabolism is negligible. |
| Patient Advice | This medication is used to reverse the blood-thinning effects of dabigatran (Pradaxa) in emergencies. · You will receive this drug intravenously (through a vein) in a hospital setting. · Inform your healthcare provider if you are pregnant, breastfeeding, or have any allergies. · After treatment, your blood clotting function will be monitored closely. · Possible side effects include headache, fever, and reactions at the injection site; seek help if you have signs of an allergic reaction. · You may need to restart anticoagulant therapy once the emergency is resolved; follow your doctor's instructions. |